N/A Completed N=41 Health Services Research

Remote Monitoring of Lung Cancer Patient-Reported Outcomes Using Moovcare®

Lung Cancer · Neoplasms, Lung · Neoplasms, Pulmonary · Pulmonary Cancer

Source: ClinicalTrials.gov NCT05011890 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Oct 2023

Primary outcomePrimary: Feasibility of Self-reporting Symptoms Using Moovcare® — 66.0 percentage of e-PRO surveys completed

Summary

The purpose of this study is to demonstrate how Moovcare®, a mobile medical application, can be used to monitor Patient-Reported Outcomes (PROs) related to cancer treatment, cancer complications, and cancer relapse in patients with lung cancer. PROs are symptoms directly reported by patients through the completion of a survey. Up to 50 patients undergoing treatment and/or surveillance for new or existing diagnoses of lung cancer at the University of North Carolina's Lineberger Comprehensive Cancer Center will be prospectively enrolled to the use of the mobile medical application Moovcare® for 6 months. Moovcare® is not FDA approved, and its role in improving clinical care is being studied through this research. Moovcare® automatically delivers electronic patient reported outcome (ePRO) surveys on common symptoms experienced by lung cancer patients.

Outcome Measures

Outcome	Result	p-value
PRIMARY Feasibility of Self-reporting Symptoms Using Moovcare®	66.0	—
SECONDARY Patient Satisfaction	30	—
SECONDARY Health-related Quality of Life Change	-1.01	—
SECONDARY Change in Health-related Quality of Life Lung Specific	-1.01	—
SECONDARY Participant Survey Completion Rate	58.54; 68.29; 65.85; 70.73; 72.50; 67.50	—
SECONDARY Overall Survival	39	—

Eligibility Criteria

Inclusion Criteria

18 years or older
Diagnosis of lung cancer (any histology, any stage) undergoing outpatient treatment and/or surveillance/monitoring at UNC.

This may include stage I and II patients who have completed lung resection and/or are undergoing radiation, stage II and III patients receiving neoadjuvant, adjuvant, or definitive chemotherapy, stage IV patients undergoing active therapy or monitoring, patients undergoing surveillance for treated or untreated stage I-III lung cancer, and both limited and extensive small cell lung cancer. The study team will request the confirmation of the lung cancer diagnosis from the managing clinician. Patients can be enrolled at any point in their lung cancer treatment trajectory (i.e., not just at initiation of first-line treatment) after a diagnosis of lung cancer has been assigned by the treating clinician. This may include patients assigned a diagnosis of lung cancer without a tissue diagnosis.

Speaks and understands English
Reliable access to the internet and email
Access to a mobile phone (or device that can receive text messages for registration)

Exclusion Criteria

Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent or completing study procedures
Current participation in other PRO monitoring trials
Inability to read and speak English
Current incarceration

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05011890). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.